{"id":2713,"date":"2020-01-01T12:02:00","date_gmt":"2020-01-01T11:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2020\/welche-wirkstoffgruppe-fuer-die-monotherapie-der-arteriellen-hypertonie"},"modified":"2020-01-01T12:02:00","modified_gmt":"2020-01-01T11:02:00","slug":"welche-wirkstoffgruppe-fuer-die-monotherapie-der-arteriellen-hypertonie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2020\/welche-wirkstoffgruppe-fuer-die-monotherapie-der-arteriellen-hypertonie","title":{"rendered":"Welche Wirkstoffgruppe f\u00fcr die Monotherapie der arteriellen Hypertonie?"},"content":{"rendered":"<p>Zur Einleitung einer medikament\u00f6sen Behandlung der arteriellen Hypertonie werden in Leitlinien folgende Wirkstoffgruppen empfohlen: Hemmer des Renin-Angiotensin-Aldosteron-Systems (RAAS-H), darunter Angiotensin-Converting-Enzym-Hemmer (ACE-H) und Angiotensin-II-Rezeptor-Blocker (AT-II-RB), Kalziumantagonisten (KA), Betablocker (BB) und Diuretika (Thiazide und Thiazid-artige Diuretika wie Chlortalidon und Indapamid) (1, vgl. 2). Da man davon ausgeht, dass die Wirkstoffgruppen in der Senkung der kardiovaskul\u00e4ren Morbidit\u00e4t und [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zur Einleitung einer medikament\u00f6sen Behandlung der arteriellen Hypertonie werden in Leitlinien folgende Wirkstoffgruppen empfohlen: Hemmer des Renin-Angiotensin-Aldosteron-Systems (RAAS-H), darunter Angiotensin-Converting-Enzym-Hemmer (ACE-H) und Angiotensin-II-Rezeptor-Blocker (AT-II-RB), Kalziumantagonisten (KA), Betablocker (BB) und Diuretika (Thiazide und Thiazid-artige Diuretika wie Chlortalidon und Indapamid) (1, vgl. 2). Da man davon ausgeht, dass die Wirkstoffgruppen in der Senkung der kardiovaskul\u00e4ren Morbidit\u00e4t und [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[130,316,309,312,314,313,315,438,317,320,311,307,319,310,129,128,131,350,492,325,134,5333,306,437],"class_list":["post-2713","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ace-hemmer","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-antihypertensiva","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-beta-blocker","tag-betablocker","tag-betarezeptoren-blocker","tag-chlortalidon","tag-diuretika","tag-hypertonie","tag-kalziumantagonisten","tag-legend-htn-studie","tag-sartane","tag-thiazide"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2713"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2713\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}